Multiplicom N.V. announced the launch of Clarigo™
Decentralized non-invasive prenatal test (NIPT) enables major step forward in prenatal screening
Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities.
Niel – Belgium, 22nd 2015 – Biotech company Multiplicom N.V. announced the launch of Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.